Biome Grow Inc.

OTC: BIOIF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Toronto, ONReports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 28

v0.1 · 5/100 weight · pillars only

↑ listing tenure, disclosure history · ↓ 3-yr revenue growth, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$8.4M

Employees

Market cap

$56.2k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$00 CAD2022

Net income-$8.4M-10.9M CAD2022

Operating income-$468.8k-610.0k CAD2022

Total assets$341.6k462.7k CAD2022

Liabilities$3.6M4.9M CAD2022

Equity-$3.3M-4.4M CAD2022

Revenue trend

FY2017 – FY2022 · USD

FY17

FY18

$3.5M

FY19

FY20

FY21

FY22

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Biome Grow Inc. booked $0 in FY2022 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

T2 Biosystems, Inc.——Street Capital Inc.17D Tristar Wellness Solutions Inc.——Mera Pharmaceuticals, Inc.——

Key facts

CEOKhurram Malik

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersToronto, ON

ExchangeOTC: BIOIF

Employees5

IPO date2015-10-29

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.